Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
NCT05346809
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study wants to find out if Isatuximab medicine can help patients with blood cancer called multiple myeloma or lymphoma. They will give half of the patients the usual treatment and the other half will get the usual treatment plus Isatuximab. It is decided randomly which group a patient will be in. They want to see if Isatuximab can make the immune system stronger to fight the cancer when the patient gets better from the treatment.
This study wants to find out if Isatuximab medicine can help patients with blood cancer called multiple myeloma or lymphoma. They will give half of the patients the usual treatment and the other half will get the usual treatment plus Isatuximab. It is decided randomly which group a patient will be in. They want to see if Isatuximab can make the immune system stronger to fight the cancer when the patient gets better from the treatment.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
